Top Health Tech Companies in Dublin (89)

Strong Hiring & Retention: Employee headcount is increasing over the 2023–2026 period, indicating ongoing hiring momentum. Feedback suggests workforce expansion is sustained even if the pace has moderated recently.

Market Expansion: A new Jakarta office was opened in 2026 to deepen engagement across Southeast Asia. Operations span dozens of offices in many countries, supporting customers in more than 80 countries.

Innovation-Driven Growth: New offerings such as the Data Studio AI Assistant and continued development of healthcare interoperability products point to active product investment. Feedback suggests AI and healthcare enhancements are a current strategic focus.

Profitability: Operating earnings and margins improved notably in 2026, with Q3 operating earnings up sharply year over year and the operating margin rising to 5.6%. Feedback suggests earnings resilience is being supported by operational changes and a shifting business mix.

Strong Revenue Growth: Reported annual revenue expanded from $226.6B in 2023 to $270.6B in 2025, including roughly 12% growth in 2024 and 7% in 2025. This establishes a robust multi‑year revenue trajectory even as recent growth rates have moderated.

Cost & Operational Efficiency: Cost controls and operational improvements are described as lifting earnings despite lower revenue in 2026. Optum Health’s operating earnings rose from $41M to $735M year over year while serving fewer value‑based patients, indicating stronger execution.

Strong Revenue Growth: Broad-based segment momentum is evident, with Pharmaceutical & Specialty Solutions and the “Other” businesses posting strong year-over-year revenue increases alongside profit expansion. Growth is further supported by increased specialty-pharmaceutical volumes and added distribution capacity for complex therapies.

Profitability: Segment profit and operating earnings are rising faster than revenue in recent periods, indicating improved earnings conversion. Management’s repeated increases to non-GAAP EPS guidance reinforce the view that profitability is strengthening.

Diversified Revenue Streams: Adjacency businesses (at-Home Solutions, Nuclear & Precision Health, OptiFreight) are growing quickly and contributing meaningfully to profit growth. Portfolio expansion through acquisitions is broadening the earnings base beyond core drug distribution.

Strong Revenue Growth: Revenue accelerated to the fastest annual pace in a decade in FY2026, with momentum evident into the fourth quarter. Management’s outlook points to continued upper single‑digit organic expansion in the coming year.

Healthy Cash Flow: Strong free cash flow and a long-running pattern of dividend increases indicate durable cash generation. Recent dividend actions and ongoing cash returns underscore capacity to fund investment and tuck‑in M&A.

Strong Market Position & Advantage: Scale leadership at the top of global medtech by revenue, with breadth across Cardiovascular, Neuroscience, and Medical Surgical, supports resilience. Category strength in areas like cardiac pacing and ablation provides commercial leverage for new launches.

Cost & Operational Efficiency: Cost-savings efforts are positioned as a concrete lever to support improved earnings and fund growth priorities, with an enterprise-wide program targeting substantial savings over multiple years. Guidance frames these actions as part of a broader move toward sustained revenue and earnings improvement beginning in 2026.

Resilient & Sustainable Growth: Growth is presented as re-emerging, with management guiding to a return to modest year-over-year revenue expansion in 2026 after a softer 2025. Improving quarterly trends exiting 2025 and a baseline of modest operational growth excluding divestitures support a narrative of stabilization.

Strong Market Position & Advantage: Scale and global reach are repeatedly highlighted as a stabilizing advantage, with broad geographic coverage and a large portfolio supporting access, supply reach, and competitive standing in off-patent medicines. The strategic shift toward complex generics and specialty brands is framed as reinforcing the company’s long-term positioning against pricing pressures.

Strong Market Position & Advantage: The company is repeatedly described as a leader across core categories like syringes, prefillable drug-delivery systems, blood collection, and infusion therapy, supported by broad global reach and large installed bases. This entrenched position aids customer stickiness and supports durable demand.

Resilient & Sustainable Growth: A substantial portion of revenue comes from everyday consumables and recurring platforms, which provides steadier sales through cycles. Consistent year-over-year revenue increases and diversified end-market exposure underpin an enduring growth profile.

Future-Ready Strategy: Management is reshaping the portfolio into a pure-play MedTech company and investing in manufacturing capacity and innovation to sharpen focus on higher-value growth areas. Guidance reaffirmations and targeted segment investments indicate disciplined execution toward long-term expansion.

Strong Revenue Growth: Revenue is rising with multiple quarters of year-over-year increases, a higher 2025 premium and service revenue outlook, and record trailing-twelve-month totals.

Strong Market Position & Advantage: The company is the largest Medicaid managed care organization and the leading ACA Marketplace carrier, with nationwide operations and sustained industry recognition.

Market Expansion: Membership is growing in the ACA Marketplace and Medicare prescription drug plans, alongside ongoing footprint expansion and key state Medicaid contract wins.

Strong Revenue Growth: Reported results show double-digit growth at constant exchange rates in 2024 and 2025 with an accelerated start in Q1 2026, and guidance indicates continued expansion in 2026. This momentum spans all three therapeutic areas rather than a single product.

Profitability: Disclosures highlight expanding core operating margins above the mid-30s and rising core operating income. Guidance continues to target strong margins alongside growth.

Diversified Revenue Streams: Recent updates indicate contributions from Oncology, Rare Disease, and Neuroscience, with products excluding Somatuline growing strongly and rare disease accelerating. Strategic acquisitions and partnerships have broadened the base beyond any single legacy brand.

Investor Backing & Capital Strength: Recent investment by Blackstone of up to €250 million in December 2024 provides growth capital and signals external confidence in the firm’s expansion plans. Company statements link this funding to accelerating U.S. growth, M&A, and AI-enabled offerings.

Market Expansion: Multiple acquisitions and a sustained U.S. push (e.g., Notion Consulting, Ready Set Rocket, Precedence, Kaiser Associates) indicate ongoing geographic and service-line expansion across North America and Europe. Leadership attention to the U.S. market and a growing office footprint suggest increased depth in key geographies.

Innovation-Driven Growth: The firm is productizing AI (e.g., SiaGPT and 800+ deployable AI agents by April 2026) and launching new lines like Corporate Strategy, PE & M&A, pointing to growth via differentiated, tech-enabled delivery. Partnerships and ecosystem recognition around NVIDIA and AWS reinforce momentum in AI-driven consulting.